0001872789-26-000017
SEC filingRevenue was $221.8M (-14.4%) Gross Profit was $127.8M (-22.1%) Operating Income was $35.0M (-44.4%) Net Income was -$4.1M (-117.4%)
Revenue decreased 14.4% to $221.8 million in Q2 FY2026 from $259.0 million prior year, as management explained the drop was driven by unfavorable changes in volume, price, and contract manufacturing revenues. This reflects broader diabetes care market shifts, including healthcare delivery moving from hospitals to primary care providers, which could materially impact results. Lower volumes also drove cost of products sold down, though less proportionally, contributing to gross profit contraction while preserving a resilient 57.6% gross margin versus implied prior levels.
Operating income fell 44.4% to $35.0 million from $62.9 million, resulting in a 15.8% operating margin. The contraction highlights tested operating leverage amid revenue headwinds, with gross profit down 22.1% to $127.8 million. Management noted successful mitigation of supply disruptions through elevated inventory and other measures, ensuring uninterrupted customer supply despite global challenges.
Net income turned to a $4.1 million loss from $23.5 million profit, with diluted EPS at -$0.07 versus $0.40. The shift stems primarily from an increased effective tax rate due to changes in the level and mix of earnings, plus higher non-deductible costs, as outlined in Item 2. This earnings mix sensitivity underscores vulnerability to jurisdictional profit variations.
Net cash from operating activities strengthened to $48.3 million from $26.5 million, after $1.1 million in capital expenditures yielding $47.2 million free cash flow. Working capital changes, including those tied to referenced agreements in Note 4 (reflected in trade receivables and payables), alongside other assets/liabilities shifts from cloud computing costs, drove this outperformance. This liquidity supports resilience amid profitability pressures.
Geopolitical conflicts carry uncertain impacts on operations and financial performance, depending on duration and economic ripple effects. Potential tariffs threaten cost of goods, profit margins, and global distribution strategy given exposure to international manufacturing and markets. Management continues monitoring these alongside healthcare delivery trends for non-emergency diabetes care.